Compliance Considerations in an Active Deals Market for Medtech
June 17, 2026
11:00 AM – 12:00 PM
Explore how compliance leaders can proactively support deal activity across the transaction lifecycle with PwC.
Presented by PwC
Compliance Considerations in an Active Deals Market for Medtech
June 17, 2026
11:00 AM – 12:00 PM
Compliance Considerations in an Active Deals Market for Medtech
June 17, 2026
11:00 AM – 12:00 PM
Join PwC in this session discussing how Medtech deal activity is accelerating, and a wave of new regulatory and enforcement developments has put compliance leaders closer to the deal table than ever before. What’s expected of compliance in transactions has fundamentally changed, for both sides.
In this one-hour session, we will explore how compliance can move at the speed of the market while protecting and creating deal value with a dual lens on how acquirers embed compliance across the lifecycle and how companies positioning to be acquired can build programs that command stronger valuations.
What You’ll Cover
- State of the Medtech Deals Market
- what’s driving activity and why compliance is now a deal-value lever for both sides of the table
- Due Diligence in a Fast-Moving Environment
- Risk-based approaches, medtech red flags, and how analytics are reshaping analysis and sample selection
- Emerging Risks
- AI and digital health, cross-border regulatory complexity, and evolving enforcement priorities
- Operationalizing Compliance
- Embedding early despite limited pre-signing access, collaborating with legal, finance, and the deal team, and negotiating SPA protections
- Post-Close Integration and Value Creation
- Day 1 readiness, the integration plan, and compliance as a driver of sustainable growth
- Pitfalls and Leading Practices
- Lessons learned from recent transactions on both sides of the table
Date: Wednesday, June 17, 2026
Time: 11:00 AM – 12:00 PM ET
Location: Online
RSVP now to uncover what’s next for medtech in today’s health care landscape.
Meet the Speakers
Jamie Bzdyra, Director, Risk & Regulatory, PwC
Jaime is a Director in PwC’s Risk & Regulatory practice, where she advises medtech, healthcare, and pharmaceutical clients on compliance and anti-bribery and corruption matters across the deal lifecycle. She has led compliance due diligence engagements for medtech acquirers across numerous transactions, helping clients assess target companies’ compliance programs, identify ABAC and regulatory risks, evaluate third-party and HCP-related exposure, and translate findings into SPA protections and post-close integration plans. Her engagements have spanned strategic acquisitions, bolt-ons, and cross-border deals across Asia, Central Europe, Latin America, and North America.
James Woods, Principal, PwC
James Woods is a Principal in PwC’s Deals practice in Boston specializing in corporate finance and valuations. James is a leader in PwC’s medical device sector practice and life sciences valuation practice in the US. He has over 20 years of experience in valuation analysis and financial advisory work related to mergers and acquisitions, divestitures, corporate restructurings, capital market transactions, and strategic decision making.
Justin Will, Managing Director, Compliance, PwC
Justin is a Managing Director in our Pharma & Life Sciences Managed Services practice with more than 17 years of consulting and life sciences industry experience with a particular focus in MedTech including significant time collaborating with MedTech Industry Associations. Justin has a Bachelor of Science in Accounting from St. Joseph’s University, a Juris Doctorate from Widener University School of Law, and a Graduate Certificate from George Washington University.
Hear From Us
Sign up to receive emails highlighting our upcoming events, early registration savings, and engagement opportunities for the medical technology community.